CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 121 enrolled
Drug / intervention
Guanfacine +1 moredrug
Likely dose
Guanfacine 6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02051309
NCT02051309Phase 2Completed
CompareCT.gov

Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation

Yale University·interventional·Posted Jan 31, 2014·Updated Dec 29, 2021

In Brief

A Phase 2 clinical trial evaluating Guanfacine and Placebo for Smoking Cessation. Completed, enrolled 121 participants across 1 site.

Detailed Summary

Adult daily smokers motivated to quit smoking will be randomized to extended-release guanfacine (6mg/day) or placebo and will enroll in an 8-week treatment period combining medication with brief behavioral support. The investigators hypothesize that the active dose of guanfacine compared to placebo will increase rates of prolonged smoking abstinence at the end of the 8-week treatment phase.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 31, 2014
Enrollment StartMar 1, 2014
Primary CompletionNov 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 12.4 years ago

Interventions

Guanfacinedrug

6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.

Placebodrug